Cagrilintide

Cagrilintide: Clinical Guide to the Long-Acting Amylin Analogue

This guide reviews its mechanism, key clinical evidence, trial-derived dosing context, safety profile, and potential future role in obesity management.

What Is Cagrilintide?

Cagrilintide is a synthetic, long‑acting analog of amylin, a peptide hormone co‑secreted with insulin by pancreatic beta cells that contributes to postprandial glucose regulation and appetite control. Native amylin has a very short half‑life, limiting its therapeutic use, whereas Cagrilintide has been engineered for once‑weekly administration, unlike earlier agents such as pramlintide, which required multiple daily injections. Cagrilintide is currently in phase 3 clinical development for chronic weight management and is not yet approved by regulators such as the FDA or EMA; access remains restricted to clinical‑trial and research settings. Its pharmacologic profile and trial outcomes nonetheless suggest a potential role in next‑generation obesity treatment, particularly in fixed‑dose combination with semaglutide.

Mechanism of Action

Cagrilintide works by activating amylin receptors in the central nervous system, particularly within the hypothalamus and brainstem regions involved in hunger, satiety, and energy balance. Key mechanisms described in clinical and pharmacology studies include:

• Central appetite suppression: Amylin‑receptor activation enhances satiety signals, reducing caloric intake and meal size.
• Delayed gastric emptying: Slower gastric emptying prolongs post‑meal fullness and blunts postprandial glycemic excursions.
• Glucagon suppression: Reduced postprandial glucagon secretion contributes to improved glycemic control.

More importantly, the Cagrilintide peptide operates through pathways distinct from GLP‑1 receptor agonists such as semaglutide. GLP‑1 therapies act on incretin receptors to enhance glucose‑dependent insulin secretion, slow gastric emptying, and reduce appetite, whereas amylin‑receptor activation engages complementary neural circuits in the area postrema and hypothalamus. This mechanistic distinction underpins the rationale for combination therapy. By targeting distinct yet synergistic pathways, Cagrilintide and semaglutide together can produce greater satiety and weight loss than either agent alone, as shown in clinical trials of the fixed‑dose combination CagriSema.

Cagrilintide Clinical Trial Data

Evidence for Cagrilintide as a single agent comes primarily from a phase 2, once‑weekly, dose‑finding trial in adults with overweight or obesity. Participants were randomized to placebo, Cagrilintide 0.3–4.5 mg weekly, or liraglutide 3.0 mg daily.

• At 26 weeks, mean weight loss with Cagrilintide 4.5 mg was 8% of baseline body weight versus 3.0% with placebo (placebo‑subtracted ≈7.8 percentage points).
• Intermediate doses (1.2–2.4 mg) produced intermediate weight‑loss responses, confirming a dose‑dependent effect.
• Modest improvements in cardiometabolic markers (fasting glucose, waist circumference, and lipids) were observed as secondary endpoints, though these require confirmation in larger and longer‑term studies.

These data indicate that Cagrilintide has meaningful standalone efficacy compared with placebo and earlier weight-management agents, while also serving as a foundation for combination strategies.

Combination Therapy: CagriSema (REDEFINE Program)

The most impactful findings to date come from trials evaluating Cagrilintide in combination with semaglutide, known as CagriSema. In the phase 3 REDEFINE 1 trial, adults with obesity but without diabetes were randomized to once‑weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, Cagrilintide 2.4 mg, or placebo.

• At 68 weeks, the mean weight loss under the treatment-policy estimand was 20.4% with CagriSema, 14.9% with semaglutide 2.4 mg, 11.5% with Cagrilintide 2.4 mg, and 3.0% with placebo.
• Under the adherent "trial product" estimand, CagriSema achieved a 7% mean weight reduction, compared with 16.1% for semaglutide and 11.8% for Cagrilintide alone.

In REDEFINE 2, which enrolled adults with overweight or obesity and type 2 diabetes, CagriSema also demonstrated superior weight loss and HbA1c reductions compared with semaglutide and placebo, with average weight changes in the mid-teens-percentage range. Taken together, these results show that:

• Cagrilintide monotherapy delivers clinically meaningful weight loss (~11% at 4.5 mg).
• Combining Cagrilintide with semaglutide in CagriSema produces substantially greater reductions (~20–23% depending on the estimand and population), placing it among the most effective pharmacologic options currently in development.

Note: Trial timelines and regulatory milestones should always be confirmed at the time of publication, as data and submissions are evolving rapidly.

Cagrilintide Dosage (Clinical Trial Context)

Because Cagrilintide is not yet approved, all dosing information is derived from clinical trial protocols and should not be interpreted as prescribing guidance.

Monotherapy Doses Studied

In the phase 2 trial, once‑weekly subcutaneous Cagrilintide was evaluated at the following doses: 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg, 4.5 mg. The 4.5 mg weekly dose demonstrated the greatest efficacy, with a mean weight loss of 10.8% at 26 weeks. Dosing was titrated upwards to mitigate gastrointestinal side effects.

Combination Therapy Dosing

• Fixed regimen: 2.4 mg Cagrilintide + 2.4 mg semaglutide once weekly via subcutaneous injection.

All doses in development programs are delivered as weekly injections, with structured titration and close monitoring built into trial designs to optimize tolerability and safety. Any future clinical use would require similar attention to titration and monitoring, guided by approved labeling and guidelines once available.

Cagrilintide Benefits

Based on phase 2 and 3 trial data, the Cagrilintide peptide has demonstrated several clinically meaningful properties compared with earlier weight-management agents, particularly in combination therapy. All findings discussed below are derived from investigational trial settings; Cagrilintide is not approved for clinical use.

1. Novel Mechanism of Action

By targeting amylin receptors, the Cagrilintide peptide introduces a satiety pathway distinct from incretin‑based therapies. Amylin signaling primarily acts on the area postrema and hypothalamus to enhance meal termination, reduce food intake, and slow gastric emptying. This provides a mechanistically distinct approach that can complement GLP‑1 receptor agonists.

2. Synergistic Combination Potential

Cagrilintide demonstrates significant additive effects when combined with semaglutide as CagriSema. In REDEFINE 1, CagriSema achieved a mean weight loss of ~20–23%, clearly outperforming either component alone at matched doses. By engaging complementary CNS pathways (amylin and GLP‑1), this dual‑mechanism strategy enhances satiety and caloric restriction beyond monotherapy.

3. Once-Weekly Administration

The extended half‑life of Cagrilintide supports once‑weekly subcutaneous dosing in trial protocols, aligning with current GLP‑1‑based regimens and simplifying potential combination programs. If approved, reduced dosing frequency could support adherence and persistence in long-term weight-management programs.

4. Potential for Broader Metabolic Effects

Beyond weight reduction, Cagrilintide and CagriSema are being evaluated for additional metabolic outcomes. Early results suggest improvements in HbA1c, fasting and postprandial glucose, and some blood‑pressure parameters, particularly in individuals with type 2 diabetes. Ongoing trials will determine whether these translate into cardiovascular or renal risk‑reduction benefits.

5. High Efficacy in Clinical Trials

Monotherapy results of roughly 11% weight loss and combination results of approximately 20–23% in phase 2 and 3 trials place Cagrilintide and CagriSema among the most effective pharmacologic weight‑management interventions under investigation. These outcomes, if sustained and confirmed across broader populations, may significantly expand the therapeutic options available for people with obesity and related metabolic conditions.

Side Effects & Tolerability

Cagrilintide and CagriSema have a tolerability profile broadly similar to that of GLP‑1–based therapies, with gastrointestinal events as the most frequent adverse effects.

• Common events: Nausea, vomiting, diarrhea, constipation, and mild injection‑site reactions were the main treatment‑emergent events in phase 2 and REDEFINE trials, occurring more often than with placebo and generally in a dose‑dependent manner.
• Time course and management: These symptoms were most prominent during initiation and titration, often improving over time, and were mitigated in trials through gradual dose escalation and patient counseling.
• Discontinuations: Overall discontinuation rates were low and broadly comparable to semaglutide alone, suggesting no major new tolerability signals with the addition of Cagrilintide.

Current data therefore support continued late‑stage development, while longer‑term and post‑approval surveillance will be needed to characterize rare or delayed adverse events more fully.

Cagrilintide vs Other Weight Loss Peptides

Peptide	Mechanism	Weight Loss (%)	Approval Status	Dosing Frequency
Cagrilintide	Amylin receptor agonist	~11% mono; up to ~22–23% in combo (trial data)	Phase 3	Weekly
Semaglutide	GLP-1 receptor agonist	~15%	Approved	Weekly
Tirzepatide	Dual GIP/GLP-1 agonist	~20%	Approved	Weekly
Retatrutide	GIP/GLP-1/Glucagon agonist	~24% (trial data)	Phase 3	Weekly

Cagrilintide vs Semaglutide

Rather than serving as a direct alternative, Cagrilintide is designed to complement GLP-1 receptor agonists. CagriSema achieves greater weight loss than the benchmark GLP-1 therapy covered in the Semaglutide guide by combining amylin and incretin pathways in a single fixed-dose regimen.

Cagrilintide vs Tirzepatide

Unlike CagriSema's two-agent approach, the compound covered in the Tirzepatide guide integrates GIP and GLP-1 receptor activity into a single molecule, delivering improvements in both glycemic control and weight loss. CagriSema achieves multi-hormonal engagement through co-administration of two separate agents, adding amylin signaling to incretin pathways.

Cagrilintide vs Retatrutide

Retatrutide is a triple-agonist (GIP/GLP-1/glucagon), whereas Cagrilintide specifically targets the amylin receptor and is combined with GLP-1 agonism via semaglutide. Mechanistically, Cagrilintide offers an alternative multi-pathway approach that emphasizes satiety and gastric emptying rather than adding glucagon agonism. Researchers can explore these comparative pathways further in the Retatrutide guide. These comparisons illustrate a broader transition toward multi-receptor and multi-hormonal therapies, reflecting the complex physiology of appetite and energy regulation. Cagrilintide's role appears particularly notable in combination regimens, where it enhances outcomes without requiring a single multi-agonist molecule — a distinction relevant when considering dual GLP-1/glucagon approaches such as those covered in the Mazdutide guide.

Regulatory & Availability Status

Cagrilintide and CagriSema are in phase 3 development and, as of 2026, have not yet been approved by regulators such as the FDA or the EMA; access is limited to clinical trials and research programs. Phase 3 results from REDEFINE and related studies show that Cagrilintide monotherapy can deliver a mean weight loss of roughly 11%, and that CagriSema can achieve 20–23% weight loss, with encouraging cardiometabolic signals. If these findings are confirmed and translated into favorable regulatory decisions, Cagrilintide, particularly in fixed-dose combination with semaglutide, may become an important addition to chronic weight-management strategies. Researchers and clinicians interested in related metabolic compounds may also explore the peptides category for additional investigational therapies and research developments. For now, clinicians should view it as a promising investigational agent and stay attuned to emerging data and regulatory updates as the obesity-pharmacotherapy landscape continues to evolve.

FAQs — Cagrilintide

1. What is Cagrilintide used for?

Cagrilintide is being developed for chronic weight management in adults with obesity or overweight, with or without type 2 diabetes. In clinical trials, it works by activating amylin receptors that regulate appetite and satiety, but its current use is limited to research and trial settings.

2. Is CagriSema approved?

No. CagriSema, the fixed‑dose combination of Cagrilintide and semaglutide, remains in phase 3 clinical trials as of 2026 and is not yet approved by major regulatory authorities. Early results are highly promising, but regulatory decisions will depend on the full phase 3 data package.

3. How does Cagrilintide differ from Semaglutide?

Cagrilintide targets amylin receptors in the brainstem and hypothalamus, whereas semaglutide acts on GLP‑1 receptors. These distinct mechanisms allow for complementary effects when used together, which is why CagriSema has produced greater weight‑loss and metabolic benefits than either component alone in trials.

4. What weight loss can patients expect?

In phase 2 trials, participants receiving Cagrilintide 4.5 mg once weekly achieved a mean weight loss of 10–11% at 26 weeks, versus ~3% with placebo. In phase 3 REDEFINE 1, adults treated with CagriSema 2.4/2.4 mg achieved an average weight loss of ~20–23% at 68 weeks, depending on the analysis method. Individual responses vary, and these regimens remain investigational rather than approved treatment options.

Citations

1. Cagrilintide. National Center for Biotechnology Information website. Published 2026. https://pubchem.ncbi.nlm.nih.gov/compound/Cagrilintide
2. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomized, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. doi:10.1016/S0140-6736(21)01751-7
3. Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025;393(7):648-659. doi:10.1056/NEJMoa2502082
4. Novo Nordisk A/S. CagriSema 2.4 mg/2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in the phase 3 REDEFINE 1 trial. News release. June 21, 2025.

Disclaimer

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.